DK0875252T3 - Formuleringer af aktiveret protein C - Google Patents

Formuleringer af aktiveret protein C

Info

Publication number
DK0875252T3
DK0875252T3 DK98303311T DK98303311T DK0875252T3 DK 0875252 T3 DK0875252 T3 DK 0875252T3 DK 98303311 T DK98303311 T DK 98303311T DK 98303311 T DK98303311 T DK 98303311T DK 0875252 T3 DK0875252 T3 DK 0875252T3
Authority
DK
Denmark
Prior art keywords
formulations
activated protein
protein
activated
Prior art date
Application number
DK98303311T
Other languages
English (en)
Inventor
Andrew David Carlson
Theodore Arsay Sheliga
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0875252T3 publication Critical patent/DK0875252T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
DK98303311T 1997-04-28 1998-04-28 Formuleringer af aktiveret protein C DK0875252T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28

Publications (1)

Publication Number Publication Date
DK0875252T3 true DK0875252T3 (da) 2005-04-25

Family

ID=21936854

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98303311T DK0875252T3 (da) 1997-04-28 1998-04-28 Formuleringer af aktiveret protein C

Country Status (35)

Country Link
US (4) US6162629A (da)
EP (2) EP0875563A3 (da)
JP (2) JP4383547B2 (da)
KR (2) KR100564189B1 (da)
CN (2) CN1227025C (da)
AR (2) AR015598A1 (da)
AT (1) ATE285788T1 (da)
AU (2) AU740753C (da)
BR (2) BR9809292A (da)
CA (2) CA2287267C (da)
CO (2) CO4950523A1 (da)
CZ (1) CZ298429B6 (da)
DE (1) DE69828330T2 (da)
DK (1) DK0875252T3 (da)
EA (2) EA004881B1 (da)
EG (1) EG23685A (da)
ES (1) ES2234072T3 (da)
HK (1) HK1016472A1 (da)
HU (2) HUP0003401A3 (da)
ID (2) ID23172A (da)
IL (2) IL132502A0 (da)
IN (2) IN187157B (da)
MY (2) MY120984A (da)
NO (2) NO995134L (da)
NZ (2) NZ337828A (da)
PE (2) PE84799A1 (da)
PL (2) PL195090B1 (da)
PT (1) PT875252E (da)
SI (1) SI0875252T1 (da)
SV (2) SV1998000051A (da)
TR (2) TR199902529T2 (da)
TW (2) TW585871B (da)
UA (2) UA55448C2 (da)
WO (2) WO1998048822A1 (da)
ZA (2) ZA983496B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US6162629A (en) 1997-04-28 2000-12-19 Eli Lilly And Company Methods for processing activated protein C
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
ATE320263T1 (de) * 1998-11-13 2006-04-15 Lilly Co Eli Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
WO2000030676A1 (en) * 1998-11-23 2000-06-02 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
ES2219094T3 (es) * 1998-12-10 2004-11-16 Eli Lilly And Company Uso de proteina c para el tratamiento de la purpura trombocitopenica y el sindrome hemolitico uremico.
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) * 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
CA2462396A1 (en) 2001-09-19 2003-03-27 Oklahoma Medical Research Foundation Treatment of sepsis with tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
KR20040040489A (ko) 2001-10-15 2004-05-12 카이론 코포레이션 조직 인자 경로 억제제（ｔｆｐｉ）의 저용량 투여에 의한패혈증의 치료
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
PT2283856T (pt) 2002-06-21 2017-12-26 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
JP2006504772A (ja) * 2002-10-29 2006-02-09 アルザ・コーポレーション 安定化された固体ポリペプチド粒子
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1641487B1 (en) * 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
JP2007532486A (ja) * 2004-03-17 2007-11-15 カイロン コーポレイション 組織因子経路インヒビターの投与による重度の市中肺炎の処置
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
US9175283B2 (en) * 2006-05-31 2015-11-03 Genzyme Corporation Use polysaccharides for promotion of enzymatic activity
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
EA019345B1 (ru) * 2007-03-05 2014-03-31 Кадила Хелзкэр Лимитед Композиции, содержащие конъюгаты пэг-интерферон-альфа и рафинозу в качестве криопротектора
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
KR20190045414A (ko) * 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2242875A4 (en) * 2008-01-15 2012-04-04 Univ British Columbia PROTEIN C RS2069915 AS A SURVIVOR RESPONSE PREDICTOR AND ADMINISTRATION OF PROTEIN C OR AN ACTIVE PROTEIN C COMPOUND
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9357765B2 (en) 2012-04-03 2016-06-07 Smiths Medical Asd, Inc. Heparain-bulking agent compositions and methods thereof
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
BR112015000051A2 (pt) 2012-07-04 2017-06-27 Univ Sydney tratamento de distúrbios inflamatórios da pele
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
PT3137102T (pt) 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
EP4019007A1 (en) * 2016-06-01 2022-06-29 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
US6162629A (en) * 1997-04-28 2000-12-19 Eli Lilly And Company Methods for processing activated protein C
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
CZ381099A3 (cs) 2000-03-15
AR012010A1 (es) 2000-09-13
CA2287267A1 (en) 1998-11-05
CN1254284A (zh) 2000-05-24
KR20010020325A (ko) 2001-03-15
HUP0003401A2 (hu) 2001-02-28
TR199902529T2 (xx) 2000-02-21
CA2288143A1 (en) 1998-11-05
JP2001524111A (ja) 2001-11-27
PL336889A1 (en) 2000-07-17
CN1227025C (zh) 2005-11-16
BR9809304A (pt) 2000-10-17
EA199900979A1 (ru) 2000-06-26
PT875252E (pt) 2005-03-31
IL132325A0 (en) 2001-03-19
CZ298429B6 (cs) 2007-10-03
KR100564189B1 (ko) 2006-03-27
PL195090B1 (pl) 2007-08-31
MY120984A (en) 2005-12-30
TW585871B (en) 2004-05-01
PE84799A1 (es) 1999-09-16
US6159468A (en) 2000-12-12
PL336420A1 (en) 2000-06-19
AU740753B2 (en) 2001-11-15
SV1998000050A (es) 1999-01-13
HU224826B1 (en) 2006-02-28
JP2001527543A (ja) 2001-12-25
PL195642B1 (pl) 2007-10-31
ID23172A (id) 2000-03-23
NZ337828A (en) 2001-06-29
CO4940438A1 (es) 2000-07-24
NZ500346A (en) 2001-08-31
JP4383546B2 (ja) 2009-12-16
SI0875252T1 (en) 2005-06-30
US6162629A (en) 2000-12-19
NO995134L (no) 1999-12-21
NO995198L (no) 1999-10-25
NO995198D0 (no) 1999-10-25
DE69828330T2 (de) 2005-10-13
CN1235638C (zh) 2006-01-11
SV1998000051A (es) 1998-12-11
EP0875252A2 (en) 1998-11-04
HK1016472A1 (en) 1999-11-05
EA199900980A1 (ru) 2000-04-24
WO1998048818A1 (en) 1998-11-05
DE69828330D1 (de) 2005-02-03
AU7161898A (en) 1998-11-24
HUP0003401A3 (en) 2003-01-28
IN183798B (da) 2000-04-15
ZA983496B (en) 1999-10-25
CO4950523A1 (es) 2000-09-01
EP0875563A2 (en) 1998-11-04
US6395270B1 (en) 2002-05-28
EG23685A (en) 2007-05-09
AR015598A1 (es) 2001-05-16
MY118591A (en) 2004-12-31
IN187157B (da) 2002-02-16
HUP0100284A3 (en) 2003-08-28
EA002149B1 (ru) 2001-12-24
KR20010020242A (ko) 2001-03-15
EP0875252B1 (en) 2004-12-29
KR100450856B1 (ko) 2004-10-02
IL132502A0 (en) 2001-03-19
AU743531B2 (en) 2002-01-31
BR9809304B1 (pt) 2011-02-08
ZA983497B (en) 1999-10-25
AU7258998A (en) 1998-11-24
WO1998048822A1 (en) 1998-11-05
ES2234072T3 (es) 2005-06-16
TR199902631T2 (xx) 2000-01-21
PE86299A1 (es) 1999-09-17
IL132325A (en) 2005-07-25
CA2287267C (en) 2006-08-15
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
EP0875252A3 (en) 2000-07-26
ATE285788T1 (de) 2005-01-15
EP0875563A3 (en) 2000-08-02
ID22933A (id) 1999-12-16
NO995134D0 (no) 1999-10-21
EA004881B1 (ru) 2004-08-26
HUP0100284A2 (hu) 2001-06-28
CN1261280A (zh) 2000-07-26
AU740753C (en) 2002-10-10
CA2288143C (en) 2012-08-21
US6436397B1 (en) 2002-08-20
UA73071C2 (en) 2005-06-15
TWI242443B (en) 2005-11-01
BR9809292A (pt) 2000-07-04

Similar Documents

Publication Publication Date Title
DK0875252T3 (da) Formuleringer af aktiveret protein C
MA24473A1 (fr) Formulations
CY2006006I2 (el) Πρωτεϊνικα σκευασματα
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
DE69832185D1 (de) Dichroischer polarisator
ATA93198A (de) Fluoxetinpellets
NO20001494L (no) Overligger
ID23913A (id) Isokuinolina-isokuinolina
ID23497A (id) Kombinasi pembungkus-deterjen
DE69801399D1 (de) Urladen
DE69833135D1 (de) Triphendioxazinverbindungen
DK0862850T3 (da) Mejetærsker
ATE236897T1 (de) 3-benzylpiperidine
ATA112597A (de) Snowboard - bindung
FI974143A0 (fi) Anslutningssystem foer uppvaermningsanordningar
DE29721428U1 (de) Halteelement
ID23663A (id) Persiapan kaprolaktam
DE29713277U1 (de) Bohnenstangen-Set
ATA86797A (de) Verschleissschuh
DE29704569U1 (de) Halteelement
FR2766075B1 (fr) Combine fourchette-cuillere
FI974129A (fi) Apuväline
ATA46498A (de) Kunststoffgleitbahn
DE29716763U1 (de) Sonnenschirm
DE29715071U1 (de) Sonnenschirm